Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a class of newly introduced antidiabetic drugs with potent hypoglycemic effects. Recent evidence suggests that these drugs have extraglycemic impacts and are therefore able to provide additional benefits beyond glucose lowering. Mitochondrial dysfunction is a central facet of many disorders that negatively impacts many tissues and organs, especially in the setting of diabetes. Therefore, it would be hugely beneficial if an antidiabetic drug could also provide mitochondrial benefits to improve cellular function and reduce the risk of diabetic complications. In this review, we have surveyed the literature for possible mitochondrial benefits of SGLT2is and we discuss the possible mechanisms involved.
History
Comments
The original article is available at https://www.excli.de/Published Citation
Yaribeygi H, Maleki M, Butler AE, Jamialahamdi T, Sahebkar A. Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art . EXCLI Journal. 2023;22:53–66.Publication Date
4 January 2023External DOI
PubMed ID
36814854Department/Unit
- RCSI Bahrain
Publisher
University of MainzVersion
- Published Version (Version of Record)